(VIANEWS) – Globus Medical (GMED), Silicon Motion Technology Corporation (SIMO), Daktronics (DAKT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Globus Medical (GMED)
111.4% sales growth and 4.21% return on equity
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Earnings Per Share
As for profitability, Globus Medical has a trailing twelve months EPS of $1.07.
PE Ratio
Globus Medical has a trailing twelve months price to earnings ratio of 50.9. Meaning, the purchaser of the share is investing $50.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.21%.
2. Silicon Motion Technology Corporation (SIMO)
33.3% sales growth and 7.21% return on equity
Silicon Motion Technology Corporation, together with its subsidiaries, designs, develops, and markets NAND flash controllers for solid-state storage devices. It offers controllers for computing-grade solid state drives (SSDs), which are used in PCs and other client devices; enterprise-grade SSDs used in data centers; eMMC and UFS mobile embedded storage for use in smartphones and IoT devices; flash memory cards and flash drives for use in expandable storage; and specialized SSDs that are used in industrial, commercial, and automotive applications. It markets its controllers under the SMI brand; enterprise-grade SSDs under the Shannon Systems brand; and single-chip industrial-grade SSDs under the Ferri SSD, Ferri-eMMC, and Ferri-UFS brands. The company markets and sells its products through direct sales personnel and independent electronics distributors to NAND flash makers, module makers, hyperscalers, and OEMs. It operates in Taiwan, the United States, South Korea, China, Malaysia, Singapore, and internationally. Silicon Motion Technology Corporation was founded in 1995 and is based in Hong Kong, Hong Kong.
Earnings Per Share
As for profitability, Silicon Motion Technology Corporation has a trailing twelve months EPS of $1.58.
PE Ratio
Silicon Motion Technology Corporation has a trailing twelve months price to earnings ratio of 45.41. Meaning, the purchaser of the share is investing $45.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.21%.
3. Daktronics (DAKT)
22.3% sales growth and 25.75% return on equity
Daktronics, Inc. designs, manufactures, markets, and sells electronic display systems and related products worldwide. It operates in five segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company offers video display systems, such as displays to show various levels of video, graphics, and animation; indoor and outdoor LED video displays, including centerhung, landmark, ribbon board, and corporate office entrance displays, as well as video walls and hanging banners; mobile and modular display systems; architectural lighting and display products; indoor and outdoor scoreboards for various sports, digit displays, scoring and timing controllers, statistics software, and other related products; and timing systems for sports events primarily aquatics and track competitions, as well as swimming touchpads, race start systems, and relay take-off platforms. It also provides control components for video displays in live event applications; message displays; ITS dynamic message signs, including LED displays for road management, mass transit, and aviation applications; digit and directional displays for use in parking facilities; and sound systems for outdoor sports venues. In addition, the company offers out-of-home advertising displays comprising billboards and street furniture displays; DataTime product line that consists of outdoor time and temperature displays; and Fuelight digit displays designed for the petroleum industry. Further, it provides ADFLOW DMS systems that include indoor networked solutions for retailers, convenience stores, and other businesses; and Venus Control Suite, Show Control, Vanguard, and others, as well as maintenance and professional services related to its products. The company sells its products through direct sales and resellers. Daktronics, Inc. was founded in 1968 and is headquartered in Brookings, South Dakota.
Earnings Per Share
As for profitability, Daktronics has a trailing twelve months EPS of $1.16.
PE Ratio
Daktronics has a trailing twelve months price to earnings ratio of 7.58. Meaning, the purchaser of the share is investing $7.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.75%.
Volume
Today’s last reported volume for Daktronics is 623885 which is 5.2% below its average volume of 658113.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Daktronics’s EBITDA is 0.45.
4. Harmony Biosciences Holdings (HRMY)
20.7% sales growth and 29.63% return on equity
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Earnings Per Share
As for profitability, Harmony Biosciences Holdings has a trailing twelve months EPS of $2.47.
PE Ratio
Harmony Biosciences Holdings has a trailing twelve months price to earnings ratio of 13.16. Meaning, the purchaser of the share is investing $13.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.63%.
Yearly Top and Bottom Value
Harmony Biosciences Holdings’s stock is valued at $32.50 at 16:22 EST, way under its 52-week high of $46.77 and way above its 52-week low of $18.61.
Revenue Growth
Year-on-year quarterly revenue growth grew by 31.3%, now sitting on 582.02M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 35.4% and 37.5%, respectively.
5. OSI Systems (OSIS)
13.5% sales growth and 16.02% return on equity
OSI Systems, Inc. designs, manufactures, and sells electronic systems and components worldwide. It operates through three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, radiation detection, hold baggage and people screening, and explosive and narcotics trace detection systems under the Rapiscan Systems and AS&E names. It also provides site design, installation, training, and technical support services; and security screening solutions under the S2 name. The Healthcare segment offers patient monitoring and diagnostic cardiology systems, and related supplies and accessories under the Spacelabs name for use in critical care, emergency, and perioperative areas within hospitals, physicians' offices, medical clinics, and ambulatory surgery centers. The Optoelectronics and Manufacturing segment provides optoelectronic devices under the OSI Optoelectronics, OSI LaserDiode, OSI Laserscan, Semicoa, and Advanced Photonix names for the aerospace and defense, avionics, medical imaging and diagnostics, biochemistry analysis, pharmaceutical, nanotechnology, telecommunications, construction, and homeland security markets. It also offers electronics manufacturing services to original equipment manufacturers and end users for medical, automotive, defense, aerospace, industrial, and consumer applications under the OSI Electronics, APlus Products, Altaflex, and PFC names; and LCD displays for medical, industrial, and consumer electronics applications, as well as flex circuits for OEM customers. This segment offers laser-based remote sensing devices to detect and classify vehicles in toll and traffic management systems under the OSI Laserscan and Autosense names; and solid-state laser products for aerospace, defense, telecommunication, and medical applications under the OSI LaserDiode name. The company was incorporated in 1987 and is headquartered in Hawthorne, California.
Earnings Per Share
As for profitability, OSI Systems has a trailing twelve months EPS of $6.59.
PE Ratio
OSI Systems has a trailing twelve months price to earnings ratio of 20.07. Meaning, the purchaser of the share is investing $20.07 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.02%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 26.3%, now sitting on 1.37B for the twelve trailing months.
Yearly Top and Bottom Value
OSI Systems’s stock is valued at $132.26 at 16:22 EST, under its 52-week high of $139.90 and way higher than its 52-week low of $89.72.
Moving Average
OSI Systems’s value is above its 50-day moving average of $130.04 and higher than its 200-day moving average of $122.26.
Sales Growth
OSI Systems’s sales growth for the next quarter is 13.5%.
6. Alphabet (GOOG)
10.9% sales growth and 27.36% return on equity
Alphabet Inc. provides various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment offers products and services, including ads, Android, Chrome, hardware, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play store; and Fitbit wearable devices, Google Nest home products, Pixel phones, and other devices, as well as in the provision of YouTube non-advertising services. The Google Cloud segment offers infrastructure, platform, and other services; Google Workspace that include cloud-based collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells health technology and internet services. The company was founded in 1998 and is headquartered in Mountain View, California.
Earnings Per Share
As for profitability, Alphabet has a trailing twelve months EPS of $5.81.
PE Ratio
Alphabet has a trailing twelve months price to earnings ratio of 23.03. Meaning, the purchaser of the share is investing $23.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.36%.
Volume
Today’s last reported volume for Alphabet is 28308600 which is 21.54% above its average volume of 23291300.
Yearly Top and Bottom Value
Alphabet’s stock is valued at $133.78 at 16:22 EST, way under its 52-week high of $155.20 and way higher than its 52-week low of $89.94.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.5%, now sitting on 307.39B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 28.2% and 16%, respectively.
Previous days news about Alphabet(GOOG)
- According to CNBC on Saturday, 9 March, "Its top holdings include Nvidia, Amazon, Microsoft, Apple, Meta Platforms and Google’s parent company Alphabet – six of the "Magnificent Seven" mega-cap tech stocks that also lead ETFs that track the S&P 500."
7. Chimera Investment Corporation (CIM)
8.8% sales growth and 4.83% return on equity
Chimera Investment Corporation operates as a real estate investment trust (REIT) in the United States. The company, through its subsidiaries, invests in a portfolio of mortgage assets, including residential mortgage loans, agency and non-agency residential mortgage-backed securities, agency mortgage-backed securities secured by pools of commercial mortgage loans, and other real estate related securities. It has elected to be taxed as a REIT and would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its shareholders. The company was incorporated in 2007 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Chimera Investment Corporation has a trailing twelve months EPS of $0.23.
PE Ratio
Chimera Investment Corporation has a trailing twelve months price to earnings ratio of 19. Meaning, the purchaser of the share is investing $19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.83%.
Moving Average
Chimera Investment Corporation’s worth is below its 50-day moving average of $4.85 and way below its 200-day moving average of $5.27.
Yearly Top and Bottom Value
Chimera Investment Corporation’s stock is valued at $4.37 at 16:22 EST, way below its 52-week high of $6.49 and above its 52-week low of $4.17.
Revenue Growth
Year-on-year quarterly revenue growth declined by 60.1%, now sitting on 226.02M for the twelve trailing months.
8. Incyte Corporation (INCY)
7.6% sales growth and 12.5% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; and in-license agreements with Agenus, Merus, MacroGenics, and Syndax. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $2.65.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 22.94. Meaning, the purchaser of the share is investing $22.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.5%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Incyte Corporation’s EBITDA is 2.67.
Yearly Top and Bottom Value
Incyte Corporation’s stock is valued at $60.79 at 16:22 EST, way under its 52-week high of $76.04 and way above its 52-week low of $50.27.
Moving Average
Incyte Corporation’s value is above its 50-day moving average of $60.74 and above its 200-day moving average of $60.31.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.3%, now sitting on 3.7B for the twelve trailing months.
